U.S. Markets open in 41 mins.

Rexahn Pharmaceuticals, Inc. (RNN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.32+0.04 (+1.75%)
At close: 3:59PM EDT
People also watch
MSTXAEZSGALEIMUCINO
Full screen
Previous Close2.28
Open2.25
Bid2.15 x 200
Ask2.80 x 200
Day's Range2.25 - 2.38
52 Week Range0.13 - 4.74
Volume168,557
Avg. Volume218,032
Market Cap66.03M
Beta0.13
PE Ratio (TTM)-2.29
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Presslast month

    Rexahn posts 2Q profit

    The Rockville, Maryland-based company said it had net income of 3 cents per share. Losses, adjusted for non-recurring gains, were 17 cents per share. The company's shares closed at $1.84. A year ago, they ...

  • Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update
    SmarterAnalyst3 months ago

    Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update

    Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer (MIBC) Phase 2a trial  at the American Society of Clinical Oncology conference over the weekend. In reaction, Rodman & Renshaw Joseph Pantginis sees beneficial opportunity for bladder cancer patients and is bullish on the firm's pipeline drug, reiterating a Buy rating on shares of RNN with a $19.50 price target, which represents a 391% increase from current levels.

  • Associated Press5 months ago

    Rexahn reports 1Q loss

    The Rockville, Maryland-based company said it had a loss of 9 cents per share. Losses, adjusted for non-recurring costs, were 2 cents per share. The company's shares closed at 40 cents. A year ago, they ...